Navigation Links
Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
Date:8/17/2010

s a monotherapy and as an adjuvant agent as well," he added.

Xenon expects to conclude the phase 2 trial in Q1, 2011 with top-line data available in Q2, 2011.

About Xenon Pharmaceuticals Inc.

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in the areas of pain, cardiometabolic disease, and diseases of iron metabolism.  Xenon has multiple products in phase 1 and 2 clinical development.  For more information, visit the Company's website at www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NanoSmartâ„¢ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
2. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
3. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
4. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
5. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
6. Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program
7. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
8. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
9. Angiotech Pharmaceuticals Announces Conference Call and Webcast
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY ) ... shares of its Common Stock and Series A Convertible ... The Series A Convertible Preferred Stock is non-voting and ... conversion will be prohibited if, as a result, the ... 4.99% of the Common Stock then outstanding. As part ...
(Date:9/17/2014)... Sept. 17, 2014  MiMedx Group, Inc. (NASDAQ: ... marketer of patent protected regenerative biomaterials and bioimplants ... of another peer-reviewed clinical study.    ... Randomized Controlled Clinical Trial Evaluating the Use of ... and Multi-layer Compression Therapy vs. Multi-layer Compression Therapy ...
(Date:9/17/2014)... & Rockville, MD (PRWEB) September 17, 2014 ... a Small Business Innovation Research (SBIR) grant to support ... The award will provide ITI with approximately $255,000 over ... nuts, a leading cause of food allergy, affect over ... of anaphylaxis behind peanut allergy. Tree nut exposure is ...
(Date:9/17/2014)... 17, 2014 Alternative Fuels Americas, Inc. (AFAI) announced ... Special Purpose Vehicle in partnership with Jatro Greentech, Inc., a ... company. The SPV shall be called AFAI Jatro Green Ethiopia ... majority shareholder. The SPV shall pursue Jatropha planting and biofuels ... Ethiopia . "Although we have ...
Breaking Biology Technology:Oncothyreon Announces Proposed Public Offerings 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3
... is pleased to announce that they have acquired ... fully diluted basis. The cash consideration,will be used ... further develop,its technology., Molecular Vision is developing ... that will greatly extend the in-house tools,available to ...
... Inc.,(Nasdaq: VTIV ) today announced that Eran ... Officer, will make a presentation at the,2008 UBS ... which will,be held February 11-13, 2008. The conference ... management presentations and,extensive Q&A opportunities., inVentiv,s presentation ...
... loss of some top,talent, including Lipitor pioneer Dr. ... teaming to help speed research to fight bone ... arthritis and,osteoporosis., Velcura Therapeutics President and CEO ... work with Dr. Sliskovic and International,Discovery Sourcing Consultants, ...
Cached Biology Technology:Acrongenomics Acquires Equity Stake in Molecular Vision 2Acrongenomics Acquires Equity Stake in Molecular Vision 3inVentiv Health to Present at the 2008 UBS Global Healthcare Services Conference 2Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease 2
(Date:9/17/2014)... Kingdom forms a new crime unit designed to fight ... year over horse meat being passed off as beef ... detecting meat adulteration. They describe their approach, which represents ... Journal of Agricultural and Food Chemistry . , Hans-Ulrich ... major global economic problem. But they also say that ...
(Date:9/16/2014)... for Children,s Environmental Health at the Mailman School of ... between childhood asthma and prenatal exposure to two phthalates ... appear online in the journal Environmental Health Perspectives ... pregnancy to higher levels of the chemicals, butylbenzyl phthalate ... and 78 percent increase in risk of developing asthma ...
(Date:9/16/2014)... 2014)More than $100 trillion in cumulative public and ... dioxide (CO2)a 40 percent reduction of urban passenger ... world expands public transportation, walking and cycling in ... the University of California, Davis, and the Institute ... Further, an estimated 1.4 million early deaths could ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5
... University doctoral candidate and a National Park Service researcher ... , J. Judson "Jut" Wynne, an NAU graduate student ... Biological Science Center, and Kyle Voyles from Parashant National ... in northwestern Arizona. , The still-unnamed genus of cave ...
... living on mineral water, the glassy-winged sharpshooter consumes only ... which is feverishly working to prevent the insect's flight ... study published in the June 6 issue of Public ... Institute for Genomic Research (TIGR), the University of Arizona, ...
... approaches to genetic disease, based on cells' own ability to ... at the annual conference of the European Society of Human ... Instead of replacing a faulty gene (commonly referred to as ... therapeutic potential that already exists in human biology. , Professor ...
Cached Biology News:NAU researchers chirping over discovery of new cricket genus 2NAU researchers chirping over discovery of new cricket genus 3Surprising symbiosis: Glassy-winged sharpshooter eats with friends 2Surprising symbiosis: Glassy-winged sharpshooter eats with friends 3'Smart' genetic therapy helps the body to heal itself 2'Smart' genetic therapy helps the body to heal itself 3'Smart' genetic therapy helps the body to heal itself 4
... This personal-sized Thermal Cycler is the ideal ... a full range of PCR applications. ... affordable price. Save lab space without ... software. Industry-Standard PCR Technology You Can ...
... Salmonella typhimurium The genus Salmonella is a ... composed of Gram-negative bacilli that are facultative and ... "H" or flagellar antigen (phase 1 & 2), ... LPS moiety) and the "Vi" or capsular antigen ...
... With 36 mg/L sodium pyruvate, 50 ... 1000 mg/L glucose, calcium chloride, and magnesium ... solution (BSS) in tissue culture is generally ... In 1885, Sydney Ringer developed a solution ...
... micro 1 is a dramatic breakthrough in accurate, ... with 10nL resolution, the micro 1 has unique ... And, the micro 1 never needs re-calibration as ... Screen programming on an LCD Display , Graphical ...
Biology Products: